Korea Pfizer Pharmaceutical said Tuesday that three doses (80mcg / 20mL, 200mcg / 50mL, 400mcg / 100mL) of Precedex Premix (compound Dexmedetomidine Hydrochloride) had received approval from the Ministry of Food and Drug Safety (MFDS).

The Precedex Premix is a sedative that acts on the alpha2- adrenoceptor and is approved for use in initial intubation and artificial respiration under intensive care management, and for non-intubated patients during surgery and procedures.

The company said the new treatment has less effect on respiratory function and lowers the demand for narcotic analgesics and anesthetics in combination. In particular, it maintains the level of "light sedation" recommended by the American College of Critical Care Medicine in the management of pain, anxiety, and delirium, it added.

"We hope Precedex Premixes will be an effective treatment option for more patients, while maintaining the sedative effect of Precedex, reducing the risk of contamination or infection and adding convenience,” said Lee Hye-young, vice president of the Business Division in Korea Pfizer Essential Health. "With the approval for Precedex Premix, Korea Pfizer_{한국화이자} will strive to build a more improved portfolio for the treatment and management of intensive care patients who are on artificial respiration.